Breast cancer statistics, 2019
2019/10/02 by Carol E. DeSantis, Carol DeSantis, Jiemin Ma +6 · 37 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Global Cancer Incidence and Screening #Breast Cancer Treatment Studies #Cancer Risks and Factors
paper · pdf · doi:10.3322/caac.21583
Abstract
This article is the American Cancer Society's biennial update on female breast cancer statistics in the United States, including data on incidence, mortality, survival, and screening. Over the most recent 5-year period (2012-2016), the breast cancer incidence rate increased slightly by 0.3% per year, largely because of rising rates of local stage and hormone receptor-positive disease. In contrast, the breast cancer death rate continues to decline, dropping 40% from 1989 to 2017 and translating to 375,900 breast cancer deaths averted. Notably, the pace of the decline has slowed from an annual decrease of 1.9% during 1998 through 2011 to 1.3% during 2011 through 2017, largely driven by the trend in white women. Consequently, the black-white disparity in breast cancer mortality has remained stable since 2011 after widening over the past 3 decades. Nevertheless, the death rate remains 40% higher in blacks (28.4 vs 20.3 deaths per 100,000) despite a lower incidence rate (126.7 vs 130.8); this disparity is magnified among black women aged <50 years, who have a death rate double that of whites. In the most recent 5-year period (2013-2017), the death rate declined in Hispanics (2.1% per year), blacks (1.5%), whites (1.0%), and Asians/Pacific Islanders (0.8%) but was stable in American Indians/Alaska Natives. However, by state, breast cancer mortality rates are no longer declining in Nebraska overall; in Colorado and Wisconsin in black women; and in Nebraska, Texas, and Virginia in white women. Breast cancer was the leading cause of cancer death in women (surpassing lung cancer) in four Southern and two Midwestern states among blacks and in Utah among whites during 2016-2017. Declines in breast cancer mortality could be accelerated by expanding access to high-quality prevention, early detection, and treatment services to all women.
Citations
Cited by
- Cancer statistics for adolescents and young adults, 2020
- Cancer statistics for African American/Black People 2022
- Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer
- Cancer statistics for <scp>A</scp> merican <scp>I</scp> ndian and <scp>A</scp> laska <scp>N</scp> ative individuals, 2022: Including increasing disparities in early onset colorectal cancer
- Metabolic reprograming confers tamoxifen resistance in breast cancer
- Improved bioavailability and anticancer efficacy of Hesperetin on breast cancer via a self-assembled rebaudioside A nanomicelles system
- Using Machine Learning to Reduce the Need for Contrast Agents in Breast MRI through Synthetic Images
- Current and future burden of breast cancer: Global statistics for 2020 and 2040
- Open-Source Dataset for the RSNA Screening Mammography Cancer Detection Challenge
- Activated glucocorticoid receptor is an estrogen receptor silencer in ER+ metastatic breast cancer
- PHF20 is a Novel Prognostic Biomarker and Correlated with Immune Status in Breast Cancer
- Overexpression of TFF3 is Associated with Immune Infiltration, Molecular Subtypes, and Clinical Progression in Breast Cancer
- Overcoming Endocrine Resistance in Breast Cancer. [europepmc]
- Mechanism of RNA modification N6-methyladenosine in human cancer. [europepmc]
- Incidence Trends of Breast Cancer Molecular Subtypes by Age and Race/Ethnicity in the US From 2010 to 2016. [europepmc]
- HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer. [europepmc]
- Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities. [europepmc]
- PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects. [europepmc]
- Epidemiology of Triple-Negative Breast Cancer: A Review. [europepmc]
- Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids. [europepmc]
- Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments. [europepmc]
- Estimated Projection of US Cancer Incidence and Death to 2040. [europepmc]
- Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. [europepmc]
- The Immunology of Hormone Receptor Positive Breast Cancer. [europepmc]
- Self-assembled peptide and protein nanostructures for anti-cancer therapy: Targeted delivery, stimuli-responsive devices and immunotherapy. [europepmc]
- Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020. [europepmc]
- A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties. [europepmc]
- Tumor organoids: applications in cancer modeling and potentials in precision medicine. [europepmc]
- N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. [europepmc]
- Global guidelines for breast cancer screening: A systematic review. [europepmc]
- Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. [europepmc]
- Annual report to the nation on the status of cancer, part 1: National cancer statistics. [europepmc]
- The Single-Cell Landscape of Intratumoral Heterogeneity and The Immunosuppressive Microenvironment in Liver and Brain Metastases of Breast Cancer. [europepmc]
- The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes. [europepmc]
- A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. [europepmc]
- Therapeutic resistance to anti-oestrogen therapy in breast cancer. [europepmc]
- Current advance of nanotechnology in diagnosis and treatment for malignant tumors. [europepmc]
Related